Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.

International journal of cancer - 31 Mar 1999

Yanase K, Sugimoto Y, Andoh T, Tsuruo T

Abstract excerpt

In previous studies, we isolated a mutant DNA topoisomerase I cDNA from a camptothecin (CPT)-resistant human T-lymphoblastic leukemia cell line, CPT-K5, and demonstrated that an amino acid change from Asp to Gly at residue 533 is responsible for the CPT resistance of the enzyme. In the present study, we have constructed a bicistronic retroviral vector, Ha-TM1-IRES-neo, that carries the mutant (Gly-533) TOP1 cDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type I

Share to Glycine

Share to Neomycin

Share to Retroviridae

Share to Transduction, Genetic

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 10077164
DOI: 10.1002/(sici)1097-0215(19990331)81:1<134::aid-ijc22>3.0.co;2-y

Genes

TOP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.PMID 10077164Read ↗

Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.Semantic proximity Read ↗

Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.Semantic proximity Read ↗

Mutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plants.Semantic proximity Read ↗

Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.Semantic proximity Read ↗

DNA topoisomerase II mutations and resistance to anti-tumor drugs.Semantic proximity Read ↗

Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase IIβ in Human Leukemia K562 Cells: Generation of a Resistance Phenotype.Semantic proximity Read ↗

Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.Semantic proximity Read ↗

Directed evolution to increase camptothecin sensitivity of human DNA topoisomerase I.Semantic proximity Read ↗

Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine.Semantic proximity Read ↗

Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.Semantic proximity Read ↗

Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.Semantic proximity Read ↗

Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.